Amerikanische Gesellschaft für Hirudotherapie

A novel RGD-toxin protein, Lj-RGD3, from the buccal gland secretion of Lampetra japonica impacts diverse biological activities

Comparative biochemistry published in Biochimie (2010)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportGenomik & ProteomikSpeichel-PharmakologieWang J et al. · Biochimie, 2010

Abstract

RGD (Arg-Gly-Asp) motif toxin proteins from snake venoms, saliva glands secretion of leech or tick have typical characteristics of inhibiting platelet aggregation, angiogenesis, and tumor growth. Here we report cloning and characterization of a novel RGD-toxin protein from the buccal gland of Lampetra japonica. In an attempt to study the activities of anticoagulant in the buccal gland secretion of L. japonica, we established buccal gland cDNA library and identified a gene encoding a predicted protein of 118 amino acids with 3 RGD motifs. The predicted protein was named Lj-RGD3. We generated the cDNA of Lj-RGD3 and obtained the recombinant protein rLj-RGD3. The polyclonal antibodies against rLj-RGD3 recognized the native Lj-RGD3 protein in buccal gland secretion in Western blot analyses. The biological function studies reveal that rLj-RGD3 inhibited human platelet aggregation in a dose-dependent manner with IC(50) value at 5.277 μM. In addition, rLj-RGD3 repressed bFGF-induced angiogenesis in the chick chorioallantoic membrane model. rLj-RGD3 also inhibited the adhesion of ECV304 cells to vitronectin. Furthermore, rLj-RGD3 induced apoptosis and significantly inhibited proliferation, migration, and invasion evoked by bFGF in ECV304 cells. Taken together, these results suggested that rLj-RGD3 is a novel RGD-toxin protein possessing typical functions of the RGD-toxin protein.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAmino Acid MotifsAngiogenesis InhibitorsAnimalsAnticoagulantsAntineoplastic AgentsCells, CulturedCheekChick EmbryoDNA, ComplementaryFish VenomsGene LibraryHumans

Zusammenfassung

Lamprey (Lampetra japonica) buccal-gland RGD-toxin protein Lj-RGD3 inhibits platelet aggregation (IC50 5.3 µM), represses bFGF-induced angiogenesis, induces apoptosis, and inhibits proliferation/migration of endothelial cells — drawing biochemical parallels with leech-derived RGD toxins.

Warum dies für die Hirudotherapie relevant ist

This study cloned and characterized Lj-RGD3, a novel RGD-toxin protein with three RGD motifs, from the buccal gland of Lampetra japonica. Recombinant rLj-RGD3 inhibited human platelet aggregation in a dose-dependent manner (IC50 5.277 μM), suppressed bFGF-induced angiogenesis in the chick chorioallantoic membrane model, and inhibited ECV304 cell adhesion, proliferation, migration, and invasion. The abstract notes that RGD-motif toxin proteins with similar inhibitory activities are found in leech and tick salivary secretions, providing background context. However, the study itself involves Lampetra japonica, not leeches, and makes no direct claims about hirudotherapy or the leech secretome; its relevance to ASH's domain is limited.

Zitation

A novel RGD-toxin protein, Lj-RGD3, from the buccal gland secretion of Lampetra japonica impacts diverse biological activities.

Wang J et al. · Biochimie, 2010

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 26, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.